Myriad Genetics announces FDA approval for MyChoice CDx Test

Myriad Genetics (MYGN) announced that the FDA has approved the MyChoice CDx Test as the companion diagnostic for Zejula, a PARP inhibitor from GSK, for patients with advanced ovarian cancer. This approval is based on final data from the PRIMA trial, where the MyChoice CDx Test determined homologous recombination deficiency status and was used to stratify advanced ovarian cancer patients.